Alexis Borisy, biotech's 'man of many hats,' dons another - STAT

2022-08-08 06:57:41 By : Ms. Cathy Shen

Exclusive analysis of biotech, pharma, and the life sciences

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

In-depth analysis of biotech, pharma, and the life sciences

from some of the nation's most trusted and well-connected reporters in the industry

with STAT+ reporters and leading industry experts in our STAT+ Conversations series

hosted by STAT+, plus early-bird access and discounts to industry events around the country

get delivered to your inbox to brief you on the most important industry news of the day

like our CRISPR Trackr and Drug Pricing Policy Tracker

A lexis Borisy is the first person to admit he has a lot of projects going on. “I’m a man of many hats,” he said during a Zoom call, gesturing to one of his trademark fedoras. “My hobby is creating companies. That’s what I love to do. It soothes me.”

He left biotech venture capital firm Third Rock Ventures in 2019 to start a company dedicated to making drugs less expensive. Earlier this year, he announced he’s starting an incubator and investment firm for biotech founders named Curie Bio.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Biotech Startups and Venture Capital Reporter

Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital.

This name will appear with your comment

There was an error saving your display name. Please check and try again.

Reporting from the frontiers of health and medicine

You've been selected! Subscribe to STAT+ for less than $2 per day

Unlimited access to essential biotech, medicine, and life sciences journalism

Subscribe to STAT+ for less than $2 per day

Unlimited access to the health care news and insights you need